Commitments and Contingent Liabilities - Contingencies (Details Narrative) - USD ($) |
12 Months Ended | 24 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Aug. 11, 2020 |
Apr. 08, 2020 |
Feb. 13, 2020 |
Dec. 31, 2020 |
Dec. 31, 2016 |
Dec. 31, 2013 |
Dec. 31, 2019 |
|
| Research and development grants received | $ 162,000 | ||||||
| Grants maximum amount | $ 185,000 | ||||||
| Grants receivable | $ 110,000 | ||||||
| Description of royalty payment | The Company is required to pay royalties to IIA at a rate of 3% in the first 3-years period and 3.5% commencing from the fourth year of the proceeds from the sale of the Company's products arising from the Development Plan up to an amount equal to $272, plus annual interest equal to 12-month LIBOR applicable to dollar deposit. | ||||||
| Research and development grants | $ 272,000 | ||||||
| Accrued royalties | |||||||
| Strategic Global Research and Development, Inc [Member] | |||||||
| Litigation settlement | $ 60,000 | $ 91,000 | |||||
| Unpaid consulting fees | 71,000 | ||||||
| Unreimbursed expenses | $ 20,000 | ||||||
| Contingencies setllement, interest rate | 5.00% | ||||||
| Strategic Global Research and Development, Inc [Member] | Claim Paid Over-Time Per Month [Member] | |||||||
| Litigation settlement | $ 4,000 | ||||||
| Orot Plus Ltd [Member] | |||||||
| Stock issued by order | 2,000,000 | ||||||
| Reimbursement expenses | $ 583,000 | ||||||
| Reimbursement value added tax receivable | 10,000 | ||||||
| Orot Plus Ltd [Member] | NIS [Member] | |||||||
| Damages for lost profits | 2,000,000,000 | ||||||
| Damages value | $ 800,000 | ||||||
| X | ||||||||||
- Definition Contingencies setllement, interest rate. No definition available.
|
| X | ||||||||||
- Definition Unpaid consulting fees. No definition available.
|
| X | ||||||||||
- Definition Grants maximum amount. No definition available.
|
| X | ||||||||||
- Definition Reimbursement expenses. No definition available.
|
| X | ||||||||||
- Definition Research and development grants. No definition available.
|
| X | ||||||||||
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. No definition available.
|
| X | ||||||||||
- Definition Description of the commitment regarding royalty payment. No definition available.
|
| X | ||||||||||
- Definition Stock issued by order No definition available.
|
| X | ||||||||||
- Definition Unreimbursed expenses contingencies. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount awarded to other party in judgment or settlement of litigation. No definition available.
|
| X | ||||||||||
- Definition Amount of damages paid to the plaintiff in the legal matter. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|